BackgroundCheck.run
Search For

Daniel F Nogales, 581403 Desert View Way, Nampa, ID 83686

Daniel Nogales Phones & Addresses

1403 Desert View Way, Nampa, ID 83686   

Eugene, OR   

Alamogordo, NM   

Reno, NV   

Social networks

Daniel F Nogales

Linkedin

Work

Company: Northwest nazarene university Aug 2019 Position: Professor

Education

Degree: Doctorates, Doctor of Philosophy School / High School: University of Nevada, Reno 1987 to 1993 Specialities: Philosophy, Organic Chemistry

Skills

Teaching • Leadership • Organic Chemistry • Leadership Development

Industries

Higher Education

Mentions for Daniel F Nogales

Daniel Nogales resumes & CV records

Resumes

Daniel Nogales Photo 33

Professor

Location:
Nampa, ID
Industry:
Higher Education
Work:
Northwest Nazarene University
Professor
Northwest Nazarene University
Academic Dean
Education:
University of Nevada, Reno 1987 - 1993
Doctorates, Doctor of Philosophy, Philosophy, Organic Chemistry
Point Loma Nazarene University 1983 - 1987
Bachelors, Bachelor of Science, Chemistry
Skills:
Teaching, Leadership, Organic Chemistry, Leadership Development

Publications & IP owners

Us Patents

Azepine Synthesis Via A Diels-Alder Reaction

US Patent:
5476933, Dec 19, 1995
Filed:
Nov 16, 1994
Appl. No.:
8/341154
Inventors:
John F. W. Keana - Eugene OR
Anthony P. Guzikowski - Eugene OR
Daniel F. Nogales - Nampa ID
Sui X. Cai - Irvine CA
Assignee:
State of Oregon, acting by and through The Oregon State Board of Higher
Education, acting for and on behalf of The Oregon health Sciences
University and The University of Oregon - Eugene OR
Acea Pharmaceuticals, Inc. - Menlo Park CA
International Classification:
C07D 1504
A61K 3155
US Classification:
540521
Abstract:
Disclosed are methods of preparing azepines by a multistep synthesis including a Diels-Alder reaction. Also disclosed are methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating or preventing opiate tolerance are disclosed by administering to an animal in need of such treatment an azepine which has high binding to the NMDA glycine site.

Azepine Compounds

US Patent:
5708168, Jan 13, 1998
Filed:
Oct 17, 1995
Appl. No.:
8/544107
Inventors:
John F. W. Keana - Eugene OR
Anthony P. Guzikowski - Eugene OR
Daniel F. Nogales - Nampa ID
Sui Xiong Cai - Irvine CA
Assignee:
State of Oregon, Acting by and through The Oregon State Board of Higher
Education, Acting for and on behalf of The Oregon Health Sciences
University and The University of Oregon, Eugene Oregon - Eugene OR
ACEA Pharmaceuticals, Inc. - Irvine CA
International Classification:
C07D22316
C07D22332
A61K 3155
US Classification:
540520
Abstract:
Disclosed are methods of preparing azepines by a multistep synthesis including a Diels-Alder reaction. Also disclosed are methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating or preventing opiate tolerance are disclosed by administering to an animal in need of such treatment an azepine which has high binding to the NMDA glycine site.

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.